Reduced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fibrillation

Background: Reduced-dose rivaroxaban (10 mg) was used in the J-ROCKET AF trial, demonstrating safety in the Asian population. It remains unclear whether treatment with reduced-dose versus full-dose rivaroxaban (20 mg/15 mg) is associated with all-cause mortality in older patients with nonvalvular at...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiou, Wei-Ru, Su, Min-I, Lee, Ying-Hsiang, Lin, Po-Lin, Liu, Cheng-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607242/
https://www.ncbi.nlm.nih.gov/pubmed/37892824
http://dx.doi.org/10.3390/jcm12206686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607242/
https://www.ncbi.nlm.nih.gov/pubmed/37892824
http://dx.doi.org/10.3390/jcm12206686

Ejemplares similares